Executive team
Judith Greciet, Pharmacist, is a graduate of 3rd cycle management and pharmaceutical marketing. Judith Greciet joins from Eisai France, a company she managed as President for 3 years, and focused on high value products in the Alzheimer’s disease, a field in which it is one of the world leaders. Judith Greciet had joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (“Laboratoire Français du fractionnement et des Biotechnologies”, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she hold increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities…). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects.
Pierre Attali, MD, MSc, has been working in academic hospitals in Paris for 11 years as specialist in liver diseases before joining Synthelabo Research Clinical Department as study manager. He was rapidly promoted as project leader, group head, section head, and eventually in 1992 Head of the Clinical Research Department, managing 300-400 people in charge of clinical strategy and worldwide clinical operations. He personally brought 3 new chemical entities and several new formulations to the market, and through its management, many others. After the merger with Sanofi, he co-founded in 2000, and managed as CEO, OSMO, a CRO specialized in oncology. He then successively joined as CEO Molecular Engines Laboratories, a French biotech company dedicated to oncology, and later Urogene before joining BioAlliance. He still has medical functions in Bicêtre and Paul Brousse hospitals (Assistance Publique-Hôpitaux de Paris) where he has consultations and acts as principal investigator in several clinical trials in liver diseases. He is cofounder and board member of several specialty pharma and biotech companies.
Mr Fellmann has more than 10 years experience in the pharmaceutical industry. From 1996 to 2006, he held various positions in the finance department of Pfizer France: initially in charge of treasury operations and internal audit, he was appointed Director Treasury, Tax and Audit in 1999. In this position he was notably in charge of the management of financial risks for the French affiliate of Pfizer and he managed the financial implementation of a series of restructuring operations (including the two mergers with Warner-Lambert in 2000 and Pharmacia in 2003) as well as tax optimization schemes. From 1992 to 1995, he worked with Ernst & Young as financial auditor undertaking several assignments with customers in the industrial or financial sectors. Mr Fellmann started his carrier as deputy Finance Director at Total, Cameroon in 1990. He is a graduate of the Lyon School of Management (EM Lyon).
Michel Forest, Pharmacist, began his career in 1981 with Winthrop Laboratories where he was responsible for production and industrial Scale-up activities. In 1985, he joined the Fournier Group in Dijon to take on the building of a manufacturing plant, from its design to its international standard qualification. From 1989, he successively held various positions in the Quality Assurance area of Fournier, firstly as “Quality Assurance, Quality Control Manager”, where he created the Quality Assurance Department for Fournier’s manufacturing plants, and from 1993 as “Quality Assurance Director, Health Activities” for its global industrial activity. In 1997, Michel Forest took on the management of Quality Assurance of Scientific Affairs, from the development to the registration of products. In this role, he was involved in the international registration of pharmaceutical products, and achieved successfully several FDA inspections. In 2003, he joined “Science & Business Development”, a company dedicated to the development of pharmaceutical products, specifically in charge of Quality, Regulatory Affairs and Development Plan activities, until 2008 before joining BioAlliance Pharma.
Medical oncologist from the Institut Gustave Roussy (Villejuif cancer research institute), Louis Kayitalire started his career at Eli Lilly in France and then in the United-States, before joining Bristol Myers Squibb Corporate (US) until 2007. He has collaborated to the development of several cancer drugs, from early phases to registration, of which some are today flagship cancer treatments.
Before joining BioAlliance Pharma, Louis Kayitalire was for 5 years Vice President Clinical Research and Development Strategy for Oncology, Immunology/Inflammation and CNS/Pain at Cephalon Europe.
Aude Michel began her career as head of the Patent Department in the Technologies Transfer Office of Inserm, France's medical research agency. In 2006, she joined BioAlliance Pharma to serve as Intellectual Property Director in charge of managing all the patents and trademarks for BioAlliance as well as academic alliances, licensing activities and public granting management (OSEO-ISI, European consortium…). In 2010, she was appointed VP, Licensing & Legal Affairs.
Aude Michel holds the European Patent Qualification from European Patent Office as well as a master in biology and cellular physiology from the University of Orsay (Paris XI) and a master in Intellectual property (CEIPI, Centre for International Intellectual Property Studies).
Caroline Lemarchand has been appointed Preclinical R&D Director in November 2010. She was previously Pharmaceutical Director for the Lauriad franchise since 2006. From 2002 to 2006, she served as Project Director in charge of developing new formulations for BioAlliance Pharma most advanced products. Previously, she worked at Hoechst Marion Roussel and Novartis Pharma. Caroline Lemarchand holds a Pharm. D as well as a PhD in Pharmaceutical Sciences.
Ms Lucas joined BioAlliance Pharma as Regulatory Affairs Director in 2006. From 2000 to 2006, she served as Worldwide Regulatory Affairs Director at Agouron Pfizer in San Diego, Cal, USA, with extensive negotiations of registration dossiers with the FDA. Previously, Ms Lucas held various regulatory positions at Servier and Boehringer-Ingelheim. She holds a Pharm. D as well as a Masters Degree (DESS) of international development & registration of medicinal products.
In charge of quality assurance for all operations within the BioAlliance Pharma Group since 2006, Mrs Vivier des Vallons was responsible for the production unit of a novel pharmaceutical excipient from 2000 to 2006. In 2002, she also took the responsibility over Hygiene and Safety. She joined BioAlliance Pharma in 2000 after a chemical engineer diploma obtained from the ENSCR.